表阿霉素为主的CEOD-B联合方案治疗非霍奇金淋巴瘤临床研究  

Clinical Research of the Treatment of CEOD-B Regimen in NHL

作　　者：夏顺中[1] 刘力建[2] 刘力克[3] 

机构地区：[1]第三军医大学西南医院血液科,重庆400038 [2]中国人民解放军324医院心内科,重庆400020 [3]四川大学公共卫生学院,四川成都610041

出　　处：《中国药业》2004年第4期65-67,共3页China Pharmaceuticals

摘　　要：目的:评价不需有干细胞移植支持的以表阿霉素穴E雪为主,联合长春新碱穴O雪、环磷酰胺穴C雪、地塞米松穴D雪、博莱霉素穴B雪,治疗非霍奇金淋巴瘤穴NHL雪的方案穴CEOD-B雪,以探索一种较理想的高效、低毒的治疗方案。方法:按入院顺序将98例分成治疗组与对照组,治疗组采用CEOD-B治疗方案,对照组采用阿霉素穴H雪代替表阿霉素、其余药物不变的CHOD-B治疗方案。4个疗程后进行近期疗效评价。结果:治疗组与对照组治疗的有效率分别为91.83%及61.23%,两组差异有极显著性穴P<0.001雪;用药后两组血常规检查结果变化差异无显著性穴P>0.05雪,毒副反应中心脏毒性有差异但无显著性穴P=0.05雪,其余毒副反应无显著性差异穴P>0.05雪。结论:CEOD-B治疗方案为一高效、低毒的治疗非霍奇金淋巴瘤的理想方案。Objective:To evaluate the CEOD-B regimen(vincristine,cycloph os phamide,dexamethasone,bleomycin and epirubicin based)without the support of t he Hematopoietic Stem Cell transplantation in NHL and to find an effective and l ow poisonous regimen.Methods:Cases was equally divided into two groups.The ex perimental group adoptes CEOD-B regimen and the control group adoptes improved CHOD-B regimen in which epirubicin is replaced by adriamycin.Observe the cases for four treatment courses and evaluate the effect.Results:The effective rate of the experimental group is91.83%and that of the control group is61. 23%.There is significant difference between the two groups(P<0.01).N o significant blood RT index difference is between the two groups(P>0.05) .Regard as side effect,there is no significant difference(P>0.05)except heart toxicity(P=0.05).Conclusion:CEOD-B regimen is an effective and low poisonous regimen in the therapy of NHL.

关 键 词：非霍奇金淋巴瘤 表阿霉素 联合化学疗法 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]